Search

Displaying results 3371 - 3380 of 5895 in total
  1. Drug

    Formebolone

    go.drugbank.com/drugs/DB01569
    IllicitInvestigational

    It has been used experimentally in the treatment of growth retardation, and has been noted to increase bone mass.

    Synonyms: 2-Formyl-17-alpha-methylandrosta-1,4-diene-11-alpha,17-beta-diol-3-one
  2. Drug

    Torasemide

    go.drugbank.com/drugs/DB00214
    ApprovedInvestigational

    Torasemide is a high-ceiling loop diuretic. Structurally, it is a pyridine-sulfonylurea used as an antihypertensive agent. Torasemide was first approved for clinical use by the FDA in 1993.

    Products: TORASEMIDE MYLAN GENERICS
  3. Drug

    Freneslerbart

    go.drugbank.com/drugs/DB19080
    Investigational

    Rhinitis Who Live With a Cat). … Freneslerbart is under investigation in clinical trial NCT04981717 (A Study to Examine the Efficacy and Safety of Anti-fel D 1 Antibodies Injections in Cat-allergic Adolescent and Adult Patients With Allergic

  4. Drug

    Icotinib

    go.drugbank.com/drugs/DB11737
    Investigational

    growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) Icotinib was approved in China by the SFDA in June, 2011 and in January 2014, Beta Pharma, Inc. was given a “May Proceed” from the US FDA to

  5. Drug

    Azintuxizumab vedotin

    go.drugbank.com/drugs/DB14847
    Investigational

    Response to Recent Cancer Treatment). … is under investigation in clinical trial NCT02951117 (A Study of Venetoclax and ABBV-838 Combination Therapy With Dexamethasone in Participants With Multiple Myeloma Whose Cancer Has Come Back or Had No

  6. Drug

    Cetuximab sarotalocan

    go.drugbank.com/drugs/DB19240
    Investigational

    Cetuximab sarotalocan is under investigation in clinical trial NCT03769506 (ASP-1929 Photoimmunotherapy (PIT) Study in Recurrent Head/Neck Cancer for Patients Who Have Failed at Least Two Lines of Therapy

  7. Drug

    Revumenib

    go.drugbank.com/drugs/DB18515
    ApprovedInvestigational

    [A264688] Aberrant KMT2A is associated with the upregulation of leukemogenic transcription pathways, notably those involving _HOXA_ genes and their co-factor _MEIS1_. … It was approved by the FDA in November 2024 for the treatment of leukemia with KMT2A aberrations,[L51868,L51863] becoming the first menin inhibitor to receive FDA approval.

  8. Drug

    Armodafinil

    go.drugbank.com/drugs/DB06413
    ApprovedInvestigational

    Armodafinil is the enantiopure of the wakefulness-promoting agent modafinil (Provigil), and is indicated to improve wakefulness in adult patients with excessive sleepiness associated with obstructive sleep

  9. Drug

    Quinfamide

    go.drugbank.com/drugs/DB12780
    Investigational

    Quinfamide has been used in trials studying the treatment of Amoebiasis and Helminthiasis.

    Mixtures: LO-BRUQUIN
  10. Drug

    Onasemnogene abeparvovec

    go.drugbank.com/drugs/DB15528
    ApprovedInvestigational

    [L9194] SMA is a rare genetic disease that affects the survival and function of motor neurons, leading to debilitating and often fatal muscle weakness. … [A187250] As there is no cure for SMA, onasemnogene abeparvovec is a disease-modifying agent that decelerates the disease progression, improves motor function, and manages the symptoms.